Filing Flows › iSpecimen (ISPC) › Takeover & LBO
Is iSpecimen (ISPC) a takeover target?
A leveraged buyout does not work for iSpecimen on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-11-05): iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products.
Why a leveraged buyout does not fit
The buyout model needs iSpecimen's revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 40% over the share price before the deal (the middle half 14.7% to 60.2%), according to the 20 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-11-05 · 8-K deal · iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products
iSpecimen's latest quarter
iSpecimen, Q2 2026: revenue $152K (-79% year over year), operating margin -897.1%, net loss $1.4M, operating cash flow −$690K. The chart follows the revenue to costs, profit and cash.
Questions
Is iSpecimen being acquired?
The latest signal on file is from 2026-11-05: iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy iSpecimen?
A leveraged buyout does not work for iSpecimen on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.